Brainderived neurotrophic factor gene polymorphisms are associated with coronary artery diseaserelated depression

Yong-Qiang Liu1, Guo-Bao Su1, Chang-Hong Duan1

  • 1Department of Cardiothoracic Surgery, The First Affiliated Hospital of Xinxiang Medical University, Weihui, Henan 453100, P.R. China.

Insights

This study found a significant association between the brain-derived neurotrophic factor (BDNF) gene SNP rs6265 and coronary artery disease-related depression (CAD-D). This discovery may aid in the early diagnosis of CAD-D and predict antidepressant treatment response.

Area of Science:

  • Genetics
  • Cardiology
  • Psychiatry

Background:

  • Depression is a known risk factor for cardiac events in patients with coronary artery disease (CAD).
  • Brain-derived neurotrophic factor (BDNF) levels are decreased in depression and implicated in CAD pathogenesis.
  • The genetic basis of depression in CAD patients requires further investigation.

Purpose of the Study:

  • To investigate the association between seven single nucleotide polymorphisms (SNPs) in the BDNF gene and coronary artery disease-related depression (CAD-D).
  • To evaluate the response to sertraline treatment in CAD patients with and without depression based on BDNF gene variations.

Main Methods:

  • Genotyping of seven BDNF gene SNPs (rs16917204, rs6265, rs7103873, rs16917237, rs56164415, rs13306221, rs10767664) in 616 CAD patients without depression and 155 CAD patients with depression.
  • Statistical analysis including chi-square tests, odds ratios, and confidence intervals to determine associations.
  • Assessment of response to an eight-week sertraline treatment regimen.

Main Results:

  • A significant association was found between BDNF gene SNP rs6265 and CAD-D (P=0.002).
  • SNP rs13306221 also showed a potential association with CAD-D (P=0.023).
  • Carriers of the A allele of rs6265 demonstrated improved response to sertraline treatment (P=0.003).

Conclusions:

  • The BDNF gene SNP rs6265 is significantly associated with coronary artery disease-related depression.
  • This genetic marker may facilitate the early diagnosis of CAD-D.
  • BDNF rs6265 genotype may predict the efficacy of sertraline treatment in CAD patients.

Related Concept Videos

Human Genetics01:28

Human Genetics

Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
1.9K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
80
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
152
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
113
Depressive Disorders: Etiology01:27

Depressive Disorders: Etiology

Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
863